Topical therapy of atopic dermatitis with a focus on pimecrolimus
نویسندگان
چکیده
Atopic dermatitis (AD) is a chronic and relapsing, inflammatory skin disease characterized by impaired barrier function immune system dysregulation that results in dryness, microbiome dysbiosis intense pruritus. It highly heterogeneous, its management demanding. Patients with AD are at greater risk of comorbidities such as attention-deficit hyperactivity disorder well other atopic diseases. Early-onset cases typically improve or resolve late childhood; however, it proposed the prevalence persistent adult-onset higher than previously thought. Basic therapy consists emollient application trigger avoidance, when insufficient, topical corticosteroids (TCS) first-line treatment. However, corticophobia/steroid aversion TCS side-effects, particularly on sensitive areas, lead to low compliance insufficient control. Several long- short-term randomized controlled daily practice studies have demonstrated calcineurin inhibitors, pimecrolimus, similar anti-inflammatory effects low-to-medium strength TCS, reduce pruritus quality life patients. In addition, pimecrolimus does not cause atrophy, steroid-sparing has good safety profile, no evidence for an increased malignancies infections. general, cream well-accepted well-tolerated, encouraging patient adherence leading use many physicians preferred children areas.
منابع مشابه
Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B.
Sir, Atopic dermatitis (AD) is associated with genetic and environmental factors, defects in the cutaneous barrier, bacterial and viral skin infections and immunological changes (1). AD influences the quality of life of both the patient and his or her family (2). Topical steroids are the gold standard treatment for AD, but their use is limited by potential adverse effects, including impairment ...
متن کاملPimecrolimus in dermatology: atopic dermatitis and beyond.
Pimecrolimus is a calcineurin inhibitor developed for the topical therapy of inflammatory skin diseases, particularly atopic dermatitis (AD). Pimecrolimus selectively targets T cells and mast cells. Pimecrolimus inhibits T-cell proliferation, as well as production and release of interleukin-2 (IL-2), IL-4, interferon-gamma and tumour necrosis factor-alpha. Moreover, pimecrolimus inhibits mast c...
متن کاملPimecrolimus 1% cream (Elidel) for atopic dermatitis.
Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases. Phase II and III clinical trials with the topical formulation of pimecrolimus (Elidel cream, Novartis) have shown that it is safe and effective for use in patients with atopic dermatitis (AD). ...
متن کاملFormulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus.
OBJECTIVE Atopic dermatitis (AD), often called eczema, is characterized by intense pruritus, erythema, dry skin, and inflammation. The condition is chronic and relapsing, and often occurs in patients with a family history of the atopic triad (asthma, allergic rhinitis, and AD). Use of topical steroids has been the mainstay of medical treatment for AD. Steroid-free treatments for AD, with a more...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of The European Academy of Dermatology and Venereology
سال: 2021
ISSN: ['1468-3083', '0926-9959']
DOI: https://doi.org/10.1111/jdv.17272